BioAtla, Inc. (BCAB) Q2 2023 Earnings Call Transcript

BioAtla, Inc. (NASDAQ:BCAB) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET

Company Participants

Bruce Mackle – IR, LifeSci Advisors, LLC

Jay Short – Chairman & Chief Medical Officer

Richard Waldron – Chief Financial Officer

Eric Sievers – Chief Medical Officer

Sheri Lydick – Chief Commercial Officer

Conference Call Participants

Brian Cheng – JPMorgan

Kaveri Pohlman – BTIG

Arthur He – H.C. Wainwright

Tony Butler – E.F. Hutton

Reni Benjamin – JMP Securities


Greetings, and welcome to the BioAtla Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Mr. Bruce Mackle with LifeSci Advisors. Thank you, Bruce. You may begin.

Bruce Mackle

Thank you, operator, and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO and Co-Founder; and Richard Waldron, Chief Financial Officer. Following today’s call, Dr. Eric Sievers, Chief Medical Officer; and Sheri Lydick, Chief Commercial Officer, will join Jay and Rick for a short Q&A. Earlier this afternoon, BioAtla released financial results and a business update for the second quarter ended June 30, 2023. A copy of the press release and corporate presentation are available on the company’s website.

Before we begin, I’d like to remind everyone that statements made during this conference call will include forward-looking statements, including, but not limited to, statements regarding BioAtla’s business plans and prospects, potential selective licensing, collaborations and other strategic partnerships, whether it’s clinical trials will be potentially registrational, achievements of milestones, results, conduct, progress and timing of its research and development programs and clinical trials; expectations with respect to enrollment and dosing in its clinical trials, plans and expectations regarding future data updates, clinical trials, regulatory meetings and regulatory submissions, the

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *